Stafford Capital Partners, established in 2000 and headquartered in London, is a boutique investment firm specializing in real assets and private markets. With a global presence, the company offers investment and advisory services to clients, focusing on sectors such as agriculture, infrastructure, private equity, sustainability, and timberland. Stafford Capital Partners is committed to responsible investing, maintaining open communication, and upholding the highest integrity in all its operations.
Founded in 2014, Locus Robotics develops autonomous mobile robots (AMRs) for fulfillment warehouses. Its flagship product, LocusBots, collaborates with human workers to enhance order productivity and accuracy by up to threefold, serving retailers, manufacturers, and logistics providers.
Britestream Networks
Series B in 2004
Britestream Networks, formerly known as Layer N Networks, specializes in innovative hardware-based data privacy solutions aimed at the security market. The company has developed a patented Instream Security Processing architecture that combines simplicity, high performance, and robust security. Britestream's semiconductor designs are tailored for network security applications, facilitating high-volume processing of secure online transmissions. Their solutions are compatible with existing infrastructure elements such as servers, firewalls, and load balancers, as well as emerging technologies like SSL VPNs and secure email gateways. By eliminating barriers to security deployment, Britestream Networks aims to provide seamless and effective internet security solutions that are automatic and easy to implement.
Xencor
Series C in 2000
Xencor is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibody therapeutics to treat severe diseases such as cancer and autoimmune disorders. The company's product pipeline includes bispecific antibodies like XmAb5871 for autoimmune diseases, plamotamab for B-cell malignancies, and XmAb20717 for various cancers.
Xencor
Series B in 1999
Xencor is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibody therapeutics to treat severe diseases such as cancer and autoimmune disorders. The company's product pipeline includes bispecific antibodies like XmAb5871 for autoimmune diseases, plamotamab for B-cell malignancies, and XmAb20717 for various cancers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.